Kiniksa Pharmaceuticals, Ltd. (KNSA) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Hamilton, Bermuda. Le PDG actuel est Sanj K. Patel.
KNSA a date d'introduction en bourse 2018-05-25, 315 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $3.48B.
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing innovative therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs. The company's product portfolio includes ARCALYST, an approved treatment for recurrent pericarditis, along with several clinical-stage candidates including Mavrilimumab for giant cell arteritis, Vixarelimab for prurigo nodularis, and KPL-404 targeting immune-mediated disorders. Founded in 2015 and headquartered in Hamilton, Bermuda, Kiniksa is committed to addressing serious inflammatory and immunological conditions with limited existing treatment options.
